SOURCE: The Alliance for Regenerative Medicine
NEW YORK, NY--(Marketwired - Mar 26, 2014) - The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the advanced therapies and regenerative medicine communities, released a comprehensive survey outlining strategic viewpoints and perspectives on regenerative medicine from 16 top pharmaceutical and large-cap biotech companies. The report was issued today at the Second Annual Regen Med Investor Day in New York City. Members of ARM's Science and Technology Committee interviewed R&D, product development and business development leadership at these companies, compiling a report that highlights the opportunities and therapeutic potential of these new technologies while also addressing major regulatory and commercialization concerns that will need to be overcome. A key finding was that all interviewed companies are actively engaged in the sector, and most view regenerative medicine as a potential paradigm shift in the development of breakthrough medicines.
"The results of this survey confirm that pharma and biotech companies see the value and long-term potential of regenerative medicine and advanced therapies, and are committed to investing in the sector through both internal research and by partnering with academia and smaller companies," said Morrie Ruffin, Managing Director of ARM. "The findings also provided valuable insights into how these companies are organizing their efforts internally, and what they see as the greatest near and long-term opportunities."
All responses were kept anonymous. The following companies participated in the survey: Allergan, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Johnson & Johnson, Merck Serono, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Genzyme and Shire.
ARM's Pharma and Biotech Survey is available online at http://alliancerm.org/page/science-and-technology and in a limited print edition. Below is a preview of the report's findings:
- 100% of the companies interviewed are investing in regenerative medicine with programs underway;
- On the therapeutic front, 69% of the companies have invested in cellular-based regenerative medicine products;
- The respondents did not have a strong preference for either allogeneic or autologous cell therapy products, stating advantages and disadvantages for either approach;
- The most common organizational structure for the companies' regenerative medicine efforts was through vertically integrated R&D units;
- The therapeutic areas considered to have the most opportunity were cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease, with wound healing and burns having, perhaps, the greatest near-term potential;
- The companies surveyed feel regenerative medicine products have the ability to succeed within current regulatory constructs;
- Product consistency and lack of standards is possibly the single greatest challenge facing the field;
- Many feel the difficult financing market has impacted the ability of small companies to run high quality clinical trials.
"The support of large pharmaceutical and biotech companies is critical to the success of the regenerative medicine field, and having this valuable insight will allow us to better understand how to work with this group of companies," said Robert A. Preti, Ph.D., President, PCT; Chief Scientific Officer, NeoStem, Inc. and co-chair of ARM's Science and Technology Committee. "It is encouraging to see that the sector is of high interest to the group, and we are pleased with their commitment to the field."
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 155 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.